An unpredictable tsunami is approaching!
According to World Health Organization, “Antimicrobial resistance (AMR) is the ability of a microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it” As a result, common life-saving treatments like caesareans will be potentially fatal, infections persist and may spread to others.
HOSPITAL ACQUIRED INFECTIONS (HAI)
Superbugs are attacking from within hospitals!
Hospital-acquired infections or HAI’s are classified as infections a patient may contract while being treated for an unrelated issue in hospital or healthcare facility. Patients who contract HAI’s are often immune-compromised making them more susceptible to opportunistic bacteria causing infection and major complications to treatment, often causing patients to succumb to their illness.
Inventing ways to escape from ESKAPE!!
We at Polyamyna Nanotech Inc. (PNI), endeavor to develop next-generation antimicrobial technologies to prevent infections caused by deadly pathogens, especially ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens, eventually striving to address the global antimicrobial resistance (AMR) catastrophe.
Journey like this takes a strong team!
Ramesh Kumar Mani
Ramesh has obtained his Ph.D. from the Memorial University of Newfoundland, Canada. He possesses over twelve years of academic and industrial experience in developing innovative polymeric and bioceramic composites for tissue engineering and implant coating applications.
Kishan holds Ph.D from Nanyang Technological University, Singapore. He has rich research experience in antibacterial drug discovery. He successfully developed novel new antibiotic molecules, which overcome the resistance against Gram-negative bacteria.
Prof. George Zhanel
Professor: Dept. of Medical Microbiology/Infectious Diseases, Max Rady College of Medicine, University of Manitoba (1987 –present) and
Coordinator: Antimicrobial Resistance Program, Departments of Medicine and Microbiology, Health Sciences Centre and
Director: Canadian Antimicrobial Resistance Allia
Charles “Chuck” Love
Charles “Chuck” Love is the founder and CEO of Venture Sciences Group (VSG). Prior to VSG, Chuck held strategic executive roles for companies pursing cutting-edge medical technologies including the Medtronic CoreValve transcatheter heart valve, Circulite Synergy ventricular assist system, and Endologix Nellix
Latest from the blog
The word ‘collateral’ elicits an unpleasant image of unintended damages in our minds. Sometimes though, the collateral effects could be
In the early 2000s an intestinal superbug began quietly spreading through hospitals around the world causing a deadly form of diarrhea among immune
A brand new area of antibiotic drug development is on the horizon as researchers recently unlocked the molecular mechanism controlling the mysterio
The rise of multidrug resistant (MDR) pathogens is an alarming trend that is being observed around the world. This has
No openings at this time